Continued Use of Trastuzumab (Herceptin) after Progression on Prior Trastuzumab Therapy in HER-2-Positive Metastatic Breast Cancer

REFERENCES

• Cobleigh M. A., Vogel C. L., Tripathy D., Robert N. J., Scholl S., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Onc. 1999; 17(9)2639–2648, [CSA]
   PubMed Web of Science ®Google Scholar
• Vogel C. L., Cobleigh M. A., Tripathy D., Gutheil J. C., Harris L. N., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002; 20(3)719–726, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Slamon D. J., Leyland-Jones B., Shak S., Fuchs H., Paton V., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Eng. J. Med. 2001; 344(11)783–792, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Advances i n. Monoclonal Antibody Therapy for Breast Cancer. Special Session, 41st Annual Meeting of ASCO, Orlando, Florida, May, 162005
   Google Scholar
• Pegram M. D., Konecny G. E., O'Callaghan C., Beryt M., Pietras R., et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J. Natl. Cancer. Inst. 2004; 96(10)739–749, [CSA]
   PubMed Web of Science ®Google Scholar
• Jahanzeb M., Mortimer J. E., Yunus F., Irwin D. H., Speyer J., et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist. 2002; 7(5)410–417, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Burstein H. J., Harris L. N., Marcom P. K., Lambert-Falls R., Havlin K., et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J. Clin. Oncol. 2003; 21(15)2889–2895, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Esteva F. J., Valero V., Booser D., Guerra L. T., Murray J. L., et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J. Clin. Onc. 2002; 20(7)1800–1808, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. 2005; 23: 4265–4274, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy J. A., Vukelja S., Marsland T., Kimmel G., Ratnam S., et al. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clinical. Breast. Cancer. 2004; 5(2)142–147, [CSA]
   PubMedGoogle Scholar
• Pegram M. D., Pienkowski T., Northfelt D. W., Eiermann W., Patel R., et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J. Natl. Cancer. Institute. 2004; 96(10)759–769, [CSA]
   PubMed Web of Science ®Google Scholar
• Fujimoto-Ouchi K., Miyazaki T., Sekiguchi F., Mori K. Preclinical study of continuous administration of trastuzumab as combination therapy after disease progression with trastuzumab monotherapy. Proc. Am. Soc. Clin. Oncol. 2005; 23, Abs. 5062[CSA]
   Google Scholar
• Hortobagyi G. N. Optimal duration of therapy with trastuzumab. Seminars in Oncology. 2001; 28(5 Suppl. 16)33–40, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Perez E. A., Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J. Clin. Onc. 2004; 22(2)322–329, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Patterns o f. Care in Medical Oncology, Ed: Neil. Love. 2004; Vol 1(Issue 2)39–45, www:BreastCancerUpdate.com/POC, [CSA]
   Google Scholar
• Fountzilas G., Razis E., Tsavdaridis D., Karina M., Labropoulos S., et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clinical. Breast. Cancer. 2003; 4(2)120–125, [CSA]
   PubMedGoogle Scholar
• Gelmon K. A., Mackey J., Verma S., Gertler S. Z., Bangemann N., et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clinical Breast Cancer. 2004; 5(1)52–58, discussion 59-62[CSA]
   PubMedGoogle Scholar
• Tripathy D., Slamon D. J., Cobleigh M., Arnold A., Saleh M., et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J. Clin. Oncol. 2004; 22(6)1063–1070, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pietras R. J., Pegram M. D., Finn R. S., Maneval D. A., Slamon D. J. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998; 17(17)2235–2249, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Falkson G., Gelman R. S., Pandya J., et al. Eastern cooperative oncology group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J. Clin. Oncol. 1998; 16(5)1669–1676, [CSA]
   PubMed Web of Science ®Google Scholar
• Muss H. B., Case L. D., Richards F. I.I., et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N. Engl. J. Med. 1991; 325: 1342–1348, [CSA]
   PubMed Web of Science ®Google Scholar
• Falkson G., Gelman R., Glick J., et al. Reinduction with the same cytostatic treatment in patients with metastatic breast cancer: An Eastern Cooperative Oncology Group Study. J. Clin. Oncol. 1994; 12: 45–49, [CSA]
   PubMed Web of Science ®Google Scholar
• Markman M., Rothman R., Hakes T., et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 1991; 9: 389–393, [CSA]
   PubMed Web of Science ®Google Scholar
• Nahta R., Takahashi T., Ueno N. T., Hung M. C., Esteva F. J. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer. Res. 2004; 64(11)3981–3986, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nagata Y., Lan K. H., Zhou X., Tan M., Esteva F. J., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer. Cell. 2004; 6(2)117–127, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nahta R., Esteva F. J. In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells. Cancer Chemotherapy & Pharmacology. 2004; 53(2)186–190, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rugo H. S., et al. Regist HER: Results from a prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer. Breast Cancer Res. Treat. 2004, (Abst # 2042)[CSA]
   Google Scholar